At Allegheny Health Network (AHN), compassion and innovation meet. We bring together groundbreaking procedures, advanced technology, and the latest research to create new models of care that provide exceptional health care.
To refer a patient call 844-MD-REFER
Understanding the Complex Landscape of Oncology Drug Shortages
October 3rd 2023In an interview, Nathan Bahary, MD, PhD, explains what factors have contributed to the rise in oncology drug shortages, and emphasizes the importance of proactive measures moving forward, while also suggesting the importance of policy changes and increased communication.
Read More
Leukemia Awareness Month: Biomarker Testing Proves Vital at Every Stage of AML Care
September 12th 2023For Leukemia Awareness Month, Salman Fazal, MD, and Tibor Kovacsovics, MD, discussed the importance of biomarker testing and targeting in diagnosis, prognosis, and treatment of acute myeloid leukemia.
Read More
The State of the Targeted Therapy Landscape for CLL
July 26th 2023In an interview with Targeted Oncology, Cyrus M. Khan, MD reviewed the recent FDA approvals is the chronic lymphocytic leukemia space. He also discusses other FDA decisions that have recently altered the landscape for the better.
Read More
TKIs Continue to Improve the Treatment Paradigm for RAI-Refractory DTC
July 24th 2023In an interview with Targeted Oncology, Warren C. Swegal, MD, takes a deep dive into the radioactive iodine-refectory differentiated thyroid cancer treatment armamentarium, and predicts the role of key agents in the near future.
Read More
Sarcoma Awareness Month: Impact of Molecular Testing and Individualized Treatments
July 19th 2023For Sarcoma Awareness Month, Lisa B. Ercolano, MD, and Mark Agulnik, MD, discussed the importance of understanding the genomics of sarcomas and how molecular testing can be useful in this space.
Read More
Cancer Immunotherapy Month: Mismatch Repair Deficiency Shapes Tumor-Agnostic Use of Immunotherapy
June 28th 2023The pan-tumor indication for immunotherapy in patients with mismatch repair deficient/microsatellite instability-high cancers has offered new treatment options and emphasized the importance of biomarker testing.
Read More
Dramatic Changes in the RCC Landscape Underscore Importance of Molecular Profiling
June 8th 2023In an interview with Targeted Oncology, Alexander Helfand, MD discussed the current standard practice for testing patients with renal cell carcinoma and administering immunotherapy or targeted therapy.
Read More
Guidance on Treating GIST in the Second-Line and Beyond
May 30th 2023In an interview with Targeted Oncology, Alexander Helfand, MD, discussed the treatment of GIST in the second-line setting, as well as later lines, including the available options, guideline recommendations, and ongoing research.
Read More